[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This part presents the company's unaudited condensed consolidated financial statements and management's discussion and analysis [Item 1. Condensed Consolidated Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20%28unaudited%29) Unaudited consolidated financial statements and notes are presented, showing a net loss of $7.9 million for H1 2025 [Unaudited Condensed Consolidated Balance Sheets](index=3&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) This section presents the company's financial position, detailing assets, liabilities, and equity at specific reporting dates Condensed Consolidated Balance Sheet Highlights (in thousands) | Metric | June 30, 2025 | December 31, 2024 | Change ($) | Change (%) | | :----------------------------- | :------------ | :---------------- | :--------- | :--------- | | Cash and cash equivalents | $20,293 | $20,305 | $(12) | -0.06% | | Total current assets | $51,268 | $48,179 | $3,089 | 6.41% | | Total assets | $81,158 | $80,241 | $917 | 1.14% | | Total current liabilities | $40,481 | $35,175 | $5,306 | 15.09% | | Total liabilities | $61,912 | $60,172 | $1,740 | 2.89% | | Total stockholders' equity | $19,246 | $20,069 | $(823) | -4.10% | [Unaudited Condensed Consolidated Statements of Operations](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) This section outlines the company's financial performance, including revenues, expenses, and net loss over specific periods Condensed Consolidated Statements of Operations Highlights (in thousands, except per share data) | Metric | 3 Months Ended June 30, 2025 | 3 Months Ended June 30, 2024 | Change ($) | Change (%) | 6 Months Ended June 30, 2025 | 6 Months Ended June 30, 2024 | Change ($) | Change (%) | | :-------------------------------------------------- | :----------------------------- | :----------------------------- | :--------- | :--------- | :----------------------------- | :----------------------------- | :--------- | :--------- | | Product revenue, net | $15,009 | $14,855 | $154 | 1.04% | $28,148 | $27,885 | $263 | 0.94% | | Total operating expenses | $17,885 | $17,782 | $103 | 0.58% | $34,348 | $40,902 | $(6,554) | -16.02% | | Loss from operations | $(2,876) | $(2,927) | $51 | -1.74% | $(6,200) | $(13,017) | $6,817 | -52.37% | | Net loss | $(3,796) | $(3,361) | $(435) | 12.94% | $(7,869) | $(13,803) | $5,934 | -43.00% | | Basic and diluted net loss per common share | $(0.16) | $(0.17) | $0.01 | -5.88% | $(0.34) | $(0.69) | $0.35 | -50.72% | [Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity) This section details changes in the company's equity, reflecting transactions affecting capital and accumulated earnings/losses Condensed Consolidated Statements of Changes in Stockholders' Equity Highlights (in thousands) | Metric | June 30, 2025 | December 31, 2024 | Change ($) | Change (%) | | :-------------------- | :------------ | :---------------- | :--------- | :--------- | | Total Shareholders' Equity | $19,246 | $20,069 | $(823) | -4.10% | | Additional Paid-in Capital | $114,140 | $107,094 | $7,046 | 6.58% | | Accumulated Deficit | $(94,896) | $(87,027) | $(7,869) | 9.04% | - Share-based compensation for the six months ended June 30, 2025, was **$2.659 million**[14](index=14&type=chunk) - Issuance of common stock from ATM offering, net of costs, generated **$4.048 million** for the six months ended June 30, 2025[14](index=14&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section reports the company's cash inflows and outflows from operating, investing, and financing activities Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Metric | 6 Months Ended June 30, 2025 | 6 Months Ended June 30, 2024 | Change ($) | Change (%) | | :-------------------------------- | :----------------------------- | :----------------------------- | :--------- | :--------- | | Net cash used in operating activities | $(3,774) | $(10,195) | $6,421 | -62.98% | | Net cash provided by financing activities | $3,762 | $6,668 | $(2,906) | -43.58% | | Net change in cash | $(12) | $(3,527) | $3,515 | -99.66% | | Cash at the end of the period | $20,293 | $23,912 | $(3,619) | -15.13% | - Cash paid for interest increased from **$756k** in 2024 to **$1,591k** in 2025 for the six-month period[22](index=22&type=chunk) [NOTE 1. ORGANIZATION AND PLAN OF BUSINESS OPERATIONS](index=7&type=section&id=NOTE%201.%20ORGANIZATION%20AND%20PLAN%20OF%20BUSINESS%20OPERATIONS) This note describes the company's business, operational structure, and financial viability considerations - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on FDA-approved prescription dermatological products in the U.S., with a portfolio of eight drugs[23](index=23&type=chunk) - The Company is a majority-owned subsidiary of Fortress Biotech, Inc[24](index=24&type=chunk) - Cash and cash equivalents were **$20.3 million** at June 30, 2025, consistent with December 31, 2024. Working capital decreased from **$13.0 million** to **$10.8 million**[25](index=25&type=chunk) - Substantial doubt exists about the Company's ability to continue as a going concern due to recurring losses[28](index=28&type=chunk) [NOTE 2. BASIS OF PRESENTATION](index=7&type=section&id=NOTE%202.%20BASIS%20OF%20PRESENTATION) This note explains the accounting principles, consolidation policies, and significant estimates used in preparing the financial statements - The Company's consolidated financial statements include the accounts of Journey Medical Corporation and its wholly-owned subsidiary, JG Pharma, Inc[29](index=29&type=chunk) - Amortization of acquired intangible assets was reclassified from 'Cost of goods sold' to a separate line item in the consolidated statement of operations, with no impact on previously reported financial results[30](index=30&type=chunk) - The Company is an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards[31](index=31&type=chunk) - Significant estimates include provisions for coupons, chargebacks, rebates, product returns, inventory realization, valuation of intangible assets, useful lives of amortizable intangible assets, and share-based compensation[32](index=32&type=chunk) [NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES](index=9&type=section&id=NOTE%203.%20SUMMARY%20OF%20SIGNIFICANT%20ACCOUNTING%20POLICIES) This note references the company's detailed accounting policies and ongoing evaluations of new accounting standards - Significant accounting policies are described in Note 2 of the Company's 2024 Form 10-K[35](index=35&type=chunk) - The Company is evaluating ASU No. 2023-09 (Income Taxes) and ASU No. 2024-03 (Income Statement Expenses) for their potential impact on disclosures[36](index=36&type=chunk)[37](index=37&type=chunk) [NOTE 4. INVENTORY](index=11&type=section&id=NOTE%204.%20INVENTORY) This note provides a breakdown of the company's inventory, including finished goods, work-in-process, raw materials, and reserves Inventory Composition (in thousands) | Inventory Category | June 30, 2025 | December 31, 2024 | Change ($) | Change (%) | | :----------------- | :------------ | :---------------- | :--------- | :--------- | | Finished goods | $9,526 | $11,381 | $(1,855) | -16.30% | | Work-in-process | $369 | $367 | $2 | 0.54% | | Raw materials | $3,66

Second Quarter 2025 Performance Overview [Financial Performance Summary](index=1&type=section&id=Financial%20Performance%20Summary) Q2 2025 net product revenues rose to $15.0 million, gross margin improved to 67%, but increased SG&A led to a $3.8 million net loss | Financial Metric (Q2) | 2025 (Millions) | 2024 (Millions) | Change (YoY) | | :-------------------- | :-------------- | :-------------- | :----------- | | Total Net Product Revenues | $15.0 | $14.9 | +0.7% | | Gross Margin | 67% | 61% | +6 ppts | | SG&A Expenses | $11.9 | $10.3 | +$1.6 | | Net Loss | $(3.8) | $(3.4) | $(0.4) | | Net Loss Per Share (Basic & Diluted) | $(0.16) | $(0.17) | +$0.01 | [CEO Commentary and Strategic Outlook](index=1&type=section&id=CEO%20Commentary%20and%20Strategic%20Outlook) CEO highlighted Emrosi's strong Q2 2025 prescription ramp and expanding payer coverage, positioning for continued growth and operating leverage - Emrosi™ generated **$2.8 million** in net sales in its first full quarter on the market, demonstrating a strong initial prescription ramp and expanding payer coverage[1](index=1&type=chunk)[2](index=2&type=chunk) - The company believes it is well-positioned for continued growth and operating leverage in the second half of 2025 and beyond, driven by Emrosi's launch traction, improved cash generation, and a focused dermatology commercial organization[2](index=2&type=chunk) [Recent Corporate Highlights](index=2&type=section&id=Recent%20Corporate%20Highlights) Journey Medical expanded Emrosi's payer access, presented positive clinical data, joined Russell Indexes, and appointed a new COO - Expanded payer access for Emrosi™ in July 2025, covering over **100 million commercial lives** in the U.S., up from **54 million** in May 2025[9](index=9&type=chunk) - A data analysis from two Phase 3 clinical trials for Emrosi™ was presented in June 2025, confirming that body weight did not affect its efficacy for moderate-to-severe papulopustular rosacea[9](index=9&type=chunk) - Journey Medical joined the Russell 2000® and Russell 3000® Indexes in June 2025[1](index=1&type=chunk)[9](index=9&type=chunk) - Ramsey Alloush was appointed as Chief Operating Officer in April 2025[9](index=9&type=chunk) Condensed Consolidated Financial Statements [Unaudited Condensed Consolidated Balance Sheets](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) Total assets increased to $81.16 million by June 30, 2025, driven by accounts receivable, while liabilities rose and equity decreased to $19.25 million | Balance Sheet Item (Thousands) | June 30, 2025 (Thousands) | December 31, 2024 (Thousands) | Change (Thousands) | | :----------------------------- | :------------ | :---------------- | :----- | | Cash and cash equivalents | $20,293 | $20,305 | $(12) | | Accounts receivable, net | $15,644 | $10,231 | +$5,413| | Total current assets | $51,268 | $48,179 | +$3,089| | Total assets | $81,158 | $80,241 | +$917 | | Total current liabilities | $40,481 | $35,175 | +$5,306| | Total liabilities | $61,912 | $60,172 | +$1,740| | Total stockholders' equity | $19,246 | $20,069 | $(823) | [Unaudited Condensed Consolidated Statements of Operations](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2025 net product revenue slightly increased to $15.01 million, gross margin improved, but higher SG&A led to a $3.80 million net loss | Income Statement Item (Thousands) | Q2 2025 (Thousands) | Q2 2024 (Thousands) | 6M 2025 (Thousands) | 6M 2024 (Thousands) | | :-------------------------------- | :---------- | :---------- | :---------- | :---------- | | Product revenue, net | $15,009 | $14,855 | $28,148 | $27,885 | | Cost of goods sold | $4,939 | $5,727 | $9,729 | $11,728 | | Research and development | $- | $913 | $39 | $8,797 | | Selling, general and administrative | $11,882 | $10,328 | $22,451 | $18,748 | | Total operating expenses | $17,885 | $17,782 | $34,348 | $40,902 | | Loss from operations | $(2,876) | $(2,927) | $(6,200) | $(13,017) | | Net loss | $(3,796) | $(3,361) | $(7,869) | $(13,803) | | Net loss per common share (Basic & Diluted) | $(0.16) | $(0.17) | $(0.34) | $(0.69) | Non-GAAP Financial Measures [Explanation of Non-GAAP Measures](index=6&type=section&id=Explanation%20of%20Non-GAAP%20Measures) Adjusted EBITDA is used for transparency, excluding non-cash or non-recurring items like share-based compensation, non-core R&D, and asset amortization - Adjusted EBITDA is defined as net income (loss) excluding interest, taxes, depreciation, and certain other non-cash and infrequent items not considered normal, recurring operating expenses[17](index=17&type=chunk) - Management uses non-GAAP measures to provide transparency, exclude non-cash/non-recurring items, and align with institutional investor analysis, but they should supplement, not substitute, GAAP measures[19](index=19&type=chunk) - Key exclusions from Adjusted EBITDA include share-based compensation, non-core and short-term R&D expenses (e.g., Emrosi pre-approval costs), and amortization/impairments of acquired intangible assets[20](index=20&type=chunk) [Reconciliation of GAAP to Non-GAAP Adjusted EBITDA](index=7&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Adjusted%20EBITDA) Q2 2025 GAAP Net Loss of $(3.80) million adjusted to a Non-GAAP Adjusted EBITDA of $(0.48) million, a decrease from Q2 2024, by adding back non-cash items | Reconciliation Item (Thousands) | Q2 2025 (Thousands) | Q2 2024 (Thousands) | 6M 2025 (Thousands) | 6M 2024 (Thousands) | | :------------------------------ | :---------- | :---------- | :---------- | :---------- | | GAAP Net Loss | $(3,796) | $(3,361) | $(7,869) | $(13,803) | | Interest | $799 | $402 | $1,541 | $733 | | Taxes | $60 | $- | $60 | $- | | Amortization of acquired intangible assets | $1,064 | $814 | $2,129 | $1,629 | | EBITDA | $(1,873) | $(2,145) | $(4,139) | $(11,441) | | Share-based compensation | $1,336 | $1,674 | $2,659 | $3,080 | | Short-term R&D | $- | $742 | $39 | $8,482 | | Non-GAAP Adjusted EBITDA | $(476) | $309 | $(1,373) | $321 | | Non-GAAP Adjusted EBITDA per share (Basic) | $(0.02) | $0.02 | $(0.06) | $0.02 | Corporate Information [About Journey Medical Corporation](index=2&type=section&id=About%20Journey%20Medical%20Corporation) Journey Medical Corporation is a commercial-stage pharmaceutical company marketing eight FDA-approved prescription dermatological products, founded by Fortress Biotech - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription dermatological products[1](index=1&type=chunk)[8](index=8&type=chunk) - The company currently markets **eight branded FDA-approved prescription drugs** for common skin conditions[8](index=8&type=chunk) - Journey Medical is located in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO)[8](index=8&type=chunk) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) Forward-looking statements are subject to risks like regulatory challenges and Emrosi's commercialization, with no update obligation under the PSLRA - The press release includes forward-looking statements regarding growth strategy and product development, identified by words like 'anticipate,' 'believe,' 'expect,' and 'will'[11](index=11&type=chunk) - These statements are subject to risks and uncertainties, including regulatory hurdles, competition, market acceptance, reliance on third parties, and the successful commercialization of Emrosi[11](index=11&type=chunk) - The company disclaims any obligation to publicly update or revise forward-looking statements, claiming protection under the Private Securities Litigation Reform Act of 1995[11](index=11&type=chunk) [Conference Call and Webcast Information](index=2&type=section&id=Conference%20Call%20and%20Webcast%20Information) A conference call and webcast were held on August 12, 2025, at 4:30 p.m. ET to discuss financial results and provide a business update - A conference call and audio webcast were scheduled for August 12, 2025, at 4:30 p.m. ET[1](index=1&type=chunk)[5](index=5&type=chunk) - Participants could register online to receive dial-in numbers for the conference call[6](index=6&type=chunk) - A live audio webcast was accessible via the Investors section of Journey Medical's website and would be available for replay for approximately 30 days[7](index=7&type=chunk) [Company Contact Information](index=3&type=section&id=Company%20Contact%20Information) Contact details for investor relations (Jaclyn Jaffe) and media relations (Tony Plohoros) were provided for inquiries - Company Contact: Jaclyn Jaffe at (781) 652-4500 or ir@jmcderm.com[12](index=12&type=chunk) - Media Relations Contact: Tony Plohoros of 6 Degrees at (908) 591-2839 or tplohoros@6degreespr.com[12](index=12&type=chunk)

Core Insights - Journey Medical Corporation reported total revenues of $15.0 million for the second quarter of 2025, showing a slight increase from $14.9 million in the same quarter of the previous year [5] - Emrosi™ generated net sales of $2.8 million in its first full quarter on the market, indicating strong initial adoption and prescription ramp [2][5] - The company joined the Russell 2000® and Russell 3000® Indexes in June 2025, reflecting its growth and market presence [2][11] Financial Results - Total net product revenues for the second quarter of 2025 were $15.0 million, compared to $14.9 million in the prior year quarter [5] - Gross margin increased to 67% in Q2 2025 from 61% in Q2 2024, attributed to lower product costs and a favorable sales mix [5] - Selling, general and administrative expenses rose to $11.9 million in Q2 2025, up from $10.3 million in Q2 2024, primarily due to costs associated with the Emrosi launch [5] - The net loss for the second quarter was $3.8 million, or $(0.16) per share, compared to a net loss of $3.4 million, or $(0.17) per share, in the prior year [5][16] - At the end of Q2 2025, the company had $20.3 million in cash and cash equivalents, unchanged from December 31, 2024 [5] Recent Corporate Highlights - In July 2025, Journey Medical expanded payer access for Emrosi to over 100 million commercial lives in the U.S., up from 54 million in May 2025 [4] - The full commercial launch of Emrosi began on April 7, 2025, and has shown strong traction in the market [4] - Emrosi was featured in a segment on "The Balancing Act®" on Lifetime TV, highlighting treatment options for managing rosacea [11]

Core Insights - The Medical sector is showing strong performance as the earnings season concludes, particularly among large biotech companies which have reported positive second-quarter results [1][2][9] Company Performance - Gilead Sciences, Inc. reported better-than-expected second-quarter results and raised its annual guidance [2] - Amgen's second-quarter results exceeded expectations in both earnings and sales, leading to an increased revenue and earnings outlook for 2025 [2] - Regeneron also surpassed earnings and sales estimates, achieving year-over-year revenue growth despite a decline in sales of its leading drug Eylea [2] - Biogen's second-quarter results were strong, with both top and bottom-line figures beating estimates, prompting an increase in its full-year guidance [2] Earnings Expectations - Several biotech companies are expected to report earnings surprises, with a focus on three specific companies: Zevra Therapeutics, Inovio Pharmaceuticals, and Journey Medical Corporation [3][9] - The Earnings ESP methodology indicates that stocks with a positive Earnings ESP and a favorable Zacks Rank have a high chance of delivering earnings surprises [4][5] Company Highlights - **Zevra Therapeutics (ZVRA)**: Focused on therapies for rare diseases, with a strong initial uptake of its FDA-approved treatment for Niemann-Pick disease type C. ZVRA has an Earnings ESP of +58.04% and is scheduled to report on August 12, 2025 [6][7] - **Inovio Pharmaceuticals (INO)**: A clinical-stage company developing DNA medicines, with a lead candidate for treating recurrent respiratory papillomatosis. INO has an Earnings ESP of +10.76% and is also set to report on August 12, 2025 [8][10] - **Journey Medical Corporation (DERM)**: Focuses on dermatological treatments and has seen a strong start for its new oral rosacea treatment. DERM has an Earnings ESP of +14.29% and is scheduled to report on August 12, 2025 [11][12]

Core Insights - Journey Medical Corporation is set to release its second quarter 2025 financial results on August 12, 2025, after U.S. financial markets close [1] - A conference call and audio webcast will be held on the same day at 4:30 p.m. ET to discuss the financial results [1] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription products for dermatological conditions [4] - The company currently markets eight FDA-approved prescription drugs specifically for dermatological issues [4] - Founded by Fortress Biotech, Inc., Journey Medical is located in Scottsdale, Arizona, and is registered under the Securities Exchange Act of 1934 [4]

Core Viewpoint - Journey Medical Corporation (DERM) is expected to report a year-over-year increase in earnings despite flat revenues, with a consensus estimate of a quarterly loss of $0.07 per share, reflecting a 58.8% improvement compared to the previous year [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to show revenues of $14.85 million, unchanged from the same quarter last year [3]. - A positive earnings surprise is likely if the actual results exceed these expectations, while a miss could lead to a decline in stock price [2]. Estimate Revisions - The consensus EPS estimate has been revised 100% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Journey Medical is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +14.29%, suggesting a bullish outlook from analysts [12]. Earnings Surprise History - In the last reported quarter, Journey Medical was expected to post a loss of $0.24 per share but delivered a loss of -$0.18, resulting in a positive surprise of +25.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Industry Comparison - Nektar Therapeutics (NKTR), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $2.65 per share, with revenues projected to decline by 54.1% year-over-year [18]. - Nektar's consensus EPS estimate has been revised down by 1.9% in the last 30 days, and it currently has an Earnings ESP of -29.46%, making it difficult to predict a beat on the consensus EPS estimate [19].

Core Insights - Journey Medical Corporation has expanded payer coverage for its product Emrosi™ to 65% of commercial lives in the U.S., a significant increase from 29% in May 2025, which supports the growing prescription demand for the product [1][2] - The company emphasizes its targeted contracting strategy and strong clinical data as key drivers for the adoption of Emrosi, which is expected to become the standard of care for treating rosacea [2] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions, currently offering eight such products [6] - The company is based in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. [6] Product Information - Emrosi™ is indicated for the treatment of inflammatory lesions of rosacea in adults, specifically targeting papules and pustules [4] - The product is available by prescription at specialty pharmacy chains [2] Market Context - Rosacea affects over 16 million Americans and approximately 415 million people worldwide, with significant impacts on patients' self-esteem and social interactions [3] - The condition is most prevalent among adults aged 30 to 50, highlighting a substantial market opportunity for effective treatments like Emrosi [3]

Core Insights - Journey Medical Corporation will be included in the Russell 2000 and Russell 3000 Indexes effective after the close of U.S. equity markets on June 27, 2025, due to the 2025 annual Russell Index reconstitution [1][2] - The inclusion in these indexes is expected to enhance the company's visibility among investors and institutions [2] - Journey Medical's FDA-approved product, Emrosi™, for treating inflammatory lesions of rosacea, is experiencing a strong market entry, with plans to expand access and grow prescription volume [2] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [6][7] - The company currently markets eight branded FDA-approved prescription drugs aimed at treating common skin conditions [6] - Founded by Fortress Biotech, Inc., Journey Medical is based in Scottsdale, Arizona [7] Market Context - The Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization, while the Russell 2000 Index is a subset focused on small-cap companies [2] - Approximately $10.6 trillion in assets are benchmarked against Russell U.S. Indexes, which are widely utilized by investment managers and institutional investors [2]

Core Viewpoint - Emrosi™ has demonstrated efficacy in treating moderate-to-severe papulopustular rosacea, independent of body weight differences, supporting its FDA approval in November 2024 [1][6][8] Group 1: Clinical Trial Results - Data from two Phase 3 trials (MVOR-1 and MVOR-2) showed that Emrosi can be prescribed without regard to body weight, reducing potential dosing errors [2][5] - In MVOR-1, 75.5% of subjects with body weight ≤ median achieved IGA treatment success with Emrosi compared to 51.0% with doxycycline and 28.2% with placebo [4] - In MVOR-2, 65.0% of subjects with body weight > median achieved IGA treatment success with Emrosi compared to 33.9% with doxycycline and 22.6% with placebo [4] Group 2: Efficacy and Safety - Emrosi showed superior efficacy on both co-primary endpoints compared to placebo and doxycycline, with no significant differences in adverse events reported [5][6] - The most common adverse reaction was dyspepsia, occurring in ≥1% of subjects treated with Emrosi [9] Group 3: Company Overview - Journey Medical Corporation focuses on marketing FDA-approved prescription products for dermatological conditions and currently markets eight such products [11] - The company is based in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. [11]

Core Viewpoint - Journey Medical Corporation is enhancing the visibility of its FDA-approved product Emrosi™ through a feature on "The Balancing Act," aimed at educating patients and healthcare providers about its benefits in treating rosacea [2][3]. Company Overview - Journey Medical Corporation (Nasdaq: DERM) is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [8]. - The company currently markets eight FDA-approved prescription drugs targeting common skin conditions and is based in Scottsdale, Arizona [8]. Product Information - Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) is the lowest-dose oral minocycline available, approved by the FDA in November 2024 for treating inflammatory lesions of rosacea in adults [2]. - Emrosi offers an effective treatment option with a favorable safety profile and is available by prescription at specialty pharmacy chains [2]. Industry Context - Rosacea is a chronic inflammatory skin condition affecting over 16 million Americans and approximately 415 million people worldwide, primarily seen in adults aged 30 to 50 [4]. - The National Rosacea Society reports that over 90% of rosacea patients feel their condition lowers their self-confidence, with significant impacts on social and professional interactions [4].